Ligand Pharmaceuticals INC 10-K annual reports

Ligand Pharmaceuticals reports significant revenue growth in 2025, driven by its biopharmaceutical royalty aggregation strategy and key product performance, alongside strategic investments and a strong cash position.

Ligand Pharmaceuticals' FY 2024 results showcase a 27% revenue increase driven by royalty growth and strategic acquisitions, alongside key investments in pipeline expansion.

Ligand Pharmaceuticals has amended its development funding agreement with Palvella Therapeutics, providing additional funding and securing options for future product revenue streams.